Full history for every metric is available with a Kvantra account
Aravive, Inc. (ARAV)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 40 | 1 | 5 | 6 | 7 | 9 | 7 |
| Operating profit | $m | -71 | -26 | |||||
| Net profit | $m | -85 | -76 | -20 | -34 | -38 | -81 | -81 |
| EPS reported | $ | -2.22 | -1.23 | |||||
| Operating cashflow per share | $ | -1.79 | -1.79 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -1.79 | -1.79 | |||||
| Free cash flow | $m | -65 | -59 | |||||
| Net debt | $m | -47 | -9 | |||||
| Book value equity | $m | 11 | - | |||||
| Book value per share | $ | 0.29 | - | |||||
| Number of shares | m | 36.37 | 76.09 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 4.51 | 0.14 | |||||
| P/S LTM | x | 5.25 | 0.42 | |||||
| P/FCF LTM | x | -0.74 | -0.05 | |||||
| EV/EBITDA LTM | x | -0.01 | 0.06 | |||||
| EV/Sales LTM | x | 0.07 | -0.80 | |||||
| Earnings Yield LTM | % | -168.55% | -5548.2% | |||||
| FCF Yield | % | -135.57% | -2015.8% | |||||
| Quality | ||||||||
| ROE | % | -759.32% | -306.06% | |||||
| ROIC | % | -161.69% | -161.69% | |||||
| Operating margin | % | -775.28% | -775.28% | |||||
| Gross margin | % | -632.60% | -632.60% | |||||
| FCF/Sales | % | -712.38% | -712.38% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +22.78% | -19.11% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -10.38 | -24.50 | |||||
| Net Debt/EBITDA | x | 0.67 | 0.67 | |||||
| EBIT/Net interest | x | -15.40 | -15.40 | |||||
| Net debt/market cap | % | -98.76% | -289.34% | |||||
| Net debt/Equity | x | -4.45 | - | |||||
| Gross debt/equity | x | 0.59 | - | |||||
Company overview
Aravive, Inc. is a clinical-stage biopharmaceutical company, based in Houston, Texas, dedicated to discovering and developing innovative treatments for life-threatening illnesses such as cancer and fibrosis. The company's primary therapeutic candidate, batiraxcept, is an ultrahigh-affinity decoy protein engineered to disrupt the GAS6-AXL signaling pathway. This drug is currently progressing through a Phase III clinical trial for platinum-resistant recurrent ovarian cancer, and is also being evaluated in Phase Ib/II studies for clear cell renal cell carcinoma and pancreatic adenocarcinoma. Aravive also has AVB-S6 in its pipeline, a soluble Fc-fusion protein aimed at blocking the activation of the same GAS6-AXL pathway. Beyond internal development, Aravive has forged strategic partnerships. This includes a collaboration with WuXi Biologics (Hong Kong) Limited to develop novel, high-affinity bispecific antibodies targeting cancer and fibrosis. Furthermore, a license agreement with 3D Medicines Inc. grants rights to develop and commercialize products featuring batiraxcept as the sole active ingredient for human oncological diseases across mainland China, Taiwan, Hong Kong, and Macau. Originally incorporated in 2008 as Versartis, Inc., the company adopted the name Aravive, Inc. in October 2018.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Aravive, Inc. (ARAV)
Aravive, Inc. is a clinical-stage biopharmaceutical company, based in Houston, Texas, dedicated to discovering and developing innovative treatments for life-threatening illnesses such as cancer and fibrosis. The company's primary therapeutic candidate, batiraxcept, is an ultrahigh-affinity decoy protein engineered to disrupt the GAS6-AXL signaling pathway. This drug is currently progressing through a Phase III clinical trial for platinum-resistant recurrent ovarian cancer, and is also being evaluated in Phase Ib/II studies for clear cell renal cell carcinoma and pancreatic adenocarcinoma. Aravive also has AVB-S6 in its pipeline, a soluble Fc-fusion protein aimed at blocking the activation of the same GAS6-AXL pathway. Beyond internal development, Aravive has forged strategic partnerships. This includes a collaboration with WuXi Biologics (Hong Kong) Limited to develop novel, high-affinity bispecific antibodies targeting cancer and fibrosis. Furthermore, a license agreement with 3D Medicines Inc. grants rights to develop and commercialize products featuring batiraxcept as the sole active ingredient for human oncological diseases across mainland China, Taiwan, Hong Kong, and Macau. Originally incorporated in 2008 as Versartis, Inc., the company adopted the name Aravive, Inc. in October 2018.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free